| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Departments of Obstetrics and Gynecology, Pathology, and Biostatistics, University of Rochester Medical Center, Rochester, New York.
Address reprint requests to: Bruno M. Polliotti, PhD, New York University, School of Medicine, Department of Obstetrics and Gynecology, 1804 Wisteria Circle, Bellport, NY 11713; E-mail: bpolliotti{at}aol.com.
OBJECTIVE: To determine whether alterations in second-trimester maternal serum cytokine concentrations can identify women at risk for developing severe, early-onset preeclampsia.
METHODS: Patients with severe preeclampsia requiring delivery prior to 34 weeks (n = 20) were each matched by gestational age, gravidity, parity, and sample freezing time with three healthy controls who delivered at term (n = 60). By using second-trimester maternal sera originally collected for fetal aneuploidy screening, the concentrations of placental growth factor, vascular endothelial growth factor, granulocyte colony-stimulating factor, endothelin-1, and human chorionic gonadotropin were compared between patients and controls. Logistic regression analysis was used to estimate odds ratios for high versus low (median split) cytokine concentrations with respect to the development of severe, early-onset preeclampsia. Receiver operating characteristic (ROC) curves based on a second logistic regression, using actual cytokine values, were plotted to illustrate reciprocal impact on sensitivity and specificity.
RESULTS: Placental growth factor and vascular endothelial growth factor levels were significantly lower in patients than in controls. No significant differences were observed for the other cytokines. The odds ratios (with 95% confidence intervals) were 15.54 (3.29, 73.40) for vascular endothelial growth factor and 4.20 (1.35, 13.06) for placental growth factor. Receiver operating characteristic analysis of placental growth factor and vascular endothelial growth factor confirmed that both were useful in discriminating between patients and controls. Models combining both vascular endothelial growth factor and placental growth factor provided the best performance for identifying patients at risk for developing severe, early-onset preeclampsia, according to both odds ratios and ROC analyses.
CONCLUSION: Combined analysis of placental growth factor and vascular endothelial growth factor is potentially useful as a tool for early identification of patients at risk for developing severe, early-onset preeclampsia.
This article has been cited by other articles:
|
|
 |
|
  H. Masuyama, H. Nakatsukasa, N. Takamoto, and Y. Hiramatsu Correlation between Soluble Endoglin, Vascular Endothelial Growth Factor Receptor-1, and Adipocytokines in Preeclampsia J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2672 - 2679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-K. Wikstrom, A. Larsson, U. J. Eriksson, P. Nash, S. Norden-Lindeberg, and M. Olovsson Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Early-Onset and Late-Onset Preeclampsia Obstet. Gynecol., June 1, 2007; 109(6): 1368 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Widmer, J. Villar, A. Benigni, A. Conde-Agudelo, S. A. Karumanchi, and M. Lindheimer Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors: A Systematic Review Obstet. Gynecol., January 1, 2007; 109(1): 168 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Levine, C. Lam, C. Qian, K. F. Yu, S. E. Maynard, B. P. Sachs, B. M. Sibai, F. H. Epstein, R. Romero, R. Thadhani, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med., September 7, 2006; 355(10): 992 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Signore, J. L. Mills, C. Qian, K. Yu, C. Lam, F. H. Epstein, S. A. Karumanchi, and R. J. Levine Circulating Angiogenic Factors and Placental Abruption Obstet. Gynecol., August 1, 2006; 108(2): 338 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lam, K.-H. Lim, and S. A. Karumanchi Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia Hypertension, November 1, 2005; 46(5): 1077 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-N. Tsao, S.-C. Wei, Y.-N. Su, H.-C. Chou, C.-Y. Chen, and W.-S. Hsieh Excess Soluble fms-Like Tyrosine Kinase 1 and Low Platelet Counts in Premature Neonates of Preeclamptic Mothers Pediatrics, August 1, 2005; 116(2): 468 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Davison, V. Homuth, A. Jeyabalan, K. P. Conrad, S. A. Karumanchi, S. Quaggin, R. Dechend, and F. C. Luft New Aspects in the Pathophysiology of Preeclampsia J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2440 - 2448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Papazoglou, G. Galazios, M. I. Koukourakis, I. Panagopoulos, E. N. Kontomanolis, K. Papatheodorou, and E. Maltezos Vascular endothelial growth factor gene polymorphisms and pre-eclampsia Mol. Hum. Reprod., May 1, 2004; 10(5): 321 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Thadhani, J. L. Ecker, W. P. Mutter, M. Wolf, K. V. Smirnakis, V. P. Sukhatme, R. J. Levine, and S. A. Karumanchi Insulin Resistance and Alterations in Angiogenesis: Additive Insults That May Lead to Preeclampsia Hypertension, May 1, 2004; 43(5): 988 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Levine, S. E. Maynard, C. Qian, K.-H. Lim, L. J. England, K. F. Yu, E. F. Schisterman, R. Thadhani, B. P. Sachs, F. H. Epstein, et al. Circulating Angiogenic Factors and the Risk of Preeclampsia N. Engl. J. Med., February 12, 2004; 350(7): 672 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Thadhani, W. P. Mutter, M. Wolf, R. J. Levine, R. N. Taylor, V. P. Sukhatme, J. Ecker, and S. A. Karumanchi First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 770 - 775. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
